Combining Radiation and Immune Modulatory Agents in Preclinical Oncology Mouse Models
More than 50% of all cancer patients receive some sort of radiation therapy as part of their disease treatment plan. However, there remains a persistent lack of drug development with radiation combinations. In order to venture into clinical trials, many drug developers want and need preclinical validation of their strategy. The ability to gain this preclinical proof-of-concept is currently an unmet preclinical need. MI Bioresearch utilizes the Small Animal Radiation Research Platform (SARRP; Xstrahl) to provide image-guided focal beam radiation in preclinical mouse models of oncology. In this webinar, featured speakers will discuss the various models and approaches they have taken to combine focal radiation with immune modulating therapeutics. Both orthotopic and subcutaneous models have been evaluated to determine the ability of radiation to provide synergistic therapeutic benefit. In some models, they have looked at the immune cell modulation following radiation treatment and a discussion on this topic will also be included.
Who Should Attend?
Areas of interest:
- Animal Models
- Cancer/Cancer Immunotherapy/Immunology
- Translational Medicine/Translational Research
- Oncology and immuno-oncology drug discovery scientists
- Scientists developing drugs in combination with radiation
- Scientists/drug developers testing immuno-oncology drugs in combination with radiation
- Basic radiobiology and role of radiation therapy in oncology treatment
- Comparison of broad field and focal radiation in preclinical cancer models
- Sensitivity of murine syngeneic models to focal radiation
- Ability to combine radiation with checkpoint inhibitors in syngeneic models
- Ability to combine radiation with costimulatory agonists in syngeneic models
- Focal radiation and modulation of immune cell populations in syngeneic models
Dr. Maryland Franklin, Vice President, Scientific Development for MI Bioresearch, has over 20 years of experience with preclinical pharmacology models. She has expertise in the design, execution, and analysis of in vivo pharmacology studies for oncology and was a key leader in bringing four drugs into Phase I clinical trials. Dr. Franklin joined MI in early 2014, and in her current role, she is focuses on strengthening MI’s in vivo animal model capabilities, overall oncology pharmacology and immuno-oncology services, and advancing internal drug discovery knowledge.
Dr. Sarah Krueger, Scientist, Imaging Operations, has 10 years of experience in preclinical cancer models with a background in cancer biology and radiobiology. She has an intimate understanding of in vitro and in vivo pharmacology and radiobiology study execution and has worked on the development of small animal radiation models for over eight years. Dr. Krueger joined MI in mid-2016 to facilitate the growth of the focal irradiation program and add depth to the imaging team, having previous expertise in MRI, PET, SPECT, CT and optical imaging techniques.